Literature DB >> 29980907

Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy.

Jane M Armer1, Karla V Ballman2, Linda McCall3, Nathan C Armer4, Yuanlu Sun4, Tipparat Udmuangpia4, Kelly K Hunt5, Elizabeth A Mittendorf5, David R Byrd6, Thomas B Julian7, Judy C Boughey8.   

Abstract

PURPOSE: Lymphedema is a potential complication of breast cancer treatment. This longitudinal substudy aimed to prospectively assess arm measurements and symptoms following neoadjuvant chemotherapy and axillary dissection in the ACOSOG/Alliance Z1071 trial to characterize the optimal approach to define lymphedema.
METHODS: Z1071 enrolled patients with cT0-4, N1-2, M0 disease treated with neoadjuvant chemotherapy. All patients underwent axillary dissection. Bilateral limb volumes, circumferences, and related symptoms were assessed pre-surgery, 1-2 weeks post-surgery, and semiannually for 36 months. Lymphedema definitions included volume increase ≥ 10% or limb circumference increase ≥ 2 cm. Symptoms were assessed by the Lymphedema Breast Cancer Questionnaire.
RESULTS: In 488 evaluable patients, lymphedema incidence at 3 years by ≥ 10%-volume-increase was 60.3% (95% CI 55.0-66.2%) and by ≥ 2 cm-circumference increase was 75.4% (95% CI 70.8-80.2%). Symptoms of arm swelling and heaviness decreased from post-surgery for the first 18 months and then were relatively stable. The 3-year cumulative incidence of arm swelling and heaviness was 26.0% (95% CI 21.7-31.1%) and 30.9% (95% CI 26.3-36.3%), respectively. There was limited agreement between the two measurements (kappa 0.27) and between symptoms and measurements (kappa coefficients ranging from 0.05-0.09).
CONCLUSIONS: Lymphedema incidence by limb volume and circumference gradually increased over 36 months post-surgery, whereas lymphedema symptoms were much lower. These findings underscore the importance of prospective surveillance and evaluation of both limb measurements and symptom assessment. Lymphedema incidence rates varied by definition. We recommend that ≥ 10% volume change criterion be used for lymphedema evaluation for referral for specialist care. TRIAL REGISTRATION: NCT00881361.

Entities:  

Keywords:  Breast cancer survivorship; Clinical trials; Lymphedema; Neoadjuvant chemotherapy; Prospective surveillance

Mesh:

Year:  2018        PMID: 29980907      PMCID: PMC6342501          DOI: 10.1007/s00520-018-4334-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  17 in total

1.  Lymphatic remodelling in response to lymphatic injury in the hind limbs of sheep.

Authors:  Tyler S Nelson; Zhanna Nepiyushchikh; Joshua S T Hooks; Mohammad S Razavi; Tristan Lewis; Cristina C Clement; Merrilee Thoresen; Matthew T Cribb; Mindy K Ross; Rudolph L Gleason; Laura Santambrogio; John F Peroni; J Brandon Dixon
Journal:  Nat Biomed Eng       Date:  2019-12-23       Impact factor: 25.671

2.  Lymphedema Signs, Symptoms, and Diagnosis in Women Who Are in Minority and Low-Income Groups and Have Survived Breast Cancer.

Authors:  Ann Marie Flores; Jason Nelson; Lee Sowles; Rebecca G Stephenson; Kathryn Robinson; Andrea Cheville; Antoinette P Sander; William J Blot
Journal:  Phys Ther       Date:  2020-03-10

Review 3.  Use of technology to facilitate a prospective surveillance program for breast cancer-related lymphedema at the Massachusetts General Hospital.

Authors:  Lauren M Havens; Cheryl L Brunelle; Tessa C Gillespie; Madison Bernstein; Loryn K Bucci; Yara W Kassamani; Alphonse G Taghian
Journal:  Mhealth       Date:  2021-01-20

4.  Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection.

Authors:  Jane M Armer; Karla V Ballman; Linda McCall; Pamela L Ostby; Eris Zagar; Henry M Kuerer; Kelly K Hunt; Judy C Boughey
Journal:  JAMA Surg       Date:  2019-09-01       Impact factor: 14.766

Review 5.  Diagnostic Criteria for Breast Cancer-Related Lymphedema of the Upper Extremity: The Need for Universal Agreement.

Authors:  Yara W Kassamani; Cheryl L Brunelle; Tessa C Gillespie; Madison C Bernstein; Loryn K Bucci; Tracy Nassif; Alphonse G Taghian
Journal:  Ann Surg Oncol       Date:  2021-09-09       Impact factor: 5.344

6.  Prevalence and incidence of cancer related lymphedema in low and middle-income countries: a systematic review and meta-analysis.

Authors:  Eric Torgbenu; Tim Luckett; Mark A Buhagiar; Sungwon Chang; Jane L Phillips
Journal:  BMC Cancer       Date:  2020-06-29       Impact factor: 4.430

7.  A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance).

Authors:  Electra D Paskett; Jennifer Le-Rademacher; Jill M Oliveri; Heshan Liu; Drew K Seisler; Jeffrey A Sloan; Jane M Armer; Michelle J Naughton; Karen Hock; Michael Schwartz; Gary Unzeitig; Marianne Melnik; Lisa D Yee; Gini F Fleming; John R Taylor; Charles Loprinzi
Journal:  Cancer       Date:  2020-10-20       Impact factor: 6.860

8.  Integrating Symptoms Into the Diagnostic Criteria for Breast Cancer-Related Lymphedema: Applying Results From a Prospective Surveillance Program.

Authors:  Cheryl L Brunelle; Sacha A Roberts; Nora K Horick; Tessa C Gillespie; Jamie M Jacobs; Kayla M Daniell; George E Naoum; Alphonse G Taghian
Journal:  Phys Ther       Date:  2020-12-07

9.  The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment.

Authors:  Mads G Jørgensen; Navid M Toyserkani; Frederik G Hansen; Anette Bygum; Jens A Sørensen
Journal:  NPJ Breast Cancer       Date:  2021-06-01

Review 10.  Lymphedema in survivors of breast cancer.

Authors:  Lin He; Huili Qu; Qian Wu; Yuhua Song
Journal:  Oncol Lett       Date:  2020-01-16       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.